Previous close | 2.9000 |
Open | 2.9000 |
Bid | 1.0000 |
Ask | 3.6000 |
Strike | 5.00 |
Expiry date | 2024-11-15 |
Day's range | 2.9000 - 2.9100 |
Contract range | N/A |
Volume | |
Open interest | 20 |
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presenta
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has made broad contributions as a member of the CytomX executive team and is a proven cross-functional leader within the organization,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. “We are ex
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...